$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

$pvct Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022049 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$314.9K	$321.7K	$187.6K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$334.0K	$455.9K	$403.6K
YoY Change	8.88%	14.67%	3.13%
% of Gross Profit
Research & Development	$580.4K	$816.6K	$669.0K
YoY Change	-4.3%	35.44%	2.45%
% of Gross Profit
Depreciation & Amortization	$2.820K	$2.820K	$3.220K
YoY Change	-12.42%	-12.15%	0.0%
% of Gross Profit
Operating Expenses	$981.1K	$1.400M	$1.076M
YoY Change	7.05%	14.54%	2.69%
Operating Profit	-$666.2K	-$1.078M	-$1.000M
YoY Change	-36.39%	-11.79%
Interest Expense	-$46.44K	-$38.10K	-$30.24K
YoY Change	1204.49%	-91.65%	-93.83%
% of Operating Profit
Other Income/Expense, Net	-$47.08K	$139.00	-$30.86K
YoY Change	9130.98%	-100.04%
Pretax Income	-$713.3K	-$1.078M	-$1.031M
YoY Change	-32.15%	-31.76%	-38.27%
Income Tax
% Of Pretax Income
Net Earnings	-$713.3K	-$1.078M	-$1.031M
YoY Change	-32.15%	-31.76%	-38.27%
Net Earnings / Revenue	-226.51%	-335.03%	-549.5%
Basic Earnings Per Share	$0.00	$0.00	$0.00
Diluted Earnings Per Share	-$1.700K	-$2.570K	-$2.458K
COMMON SHARES
Basic Shares Outstanding	419.5M shares	419.4M shares	419.4M shares
Diluted Shares Outstanding	419.5M shares	419.4M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$67.03K	$84.27K	$173.6K
YoY Change	-73.62%	77.75%	-50.36%
Cash & Equivalents	$67.03K	$84.27K	$173.6K
Short-Term Investments
Other Short-Term Assets	$1.832M	$2.192M	$2.535M
YoY Change	629.49%	644.45%	822.07%
Inventory
Prepaid Expenses	$187.5K	$243.4K
Receivables
Other Receivables
Total Short-Term Assets	$1.899M	$2.279M	$2.712M
YoY Change	274.97%	556.28%	331.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.98K	$25.80K	$43.80K
YoY Change	-75.5%	-78.33%	-69.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$151.0K	$164.7K	$43.79K
YoY Change	61.04%	38.28%	-69.23%
TOTAL ASSETS
Total Short-Term Assets	$1.899M	$2.279M	$2.712M
Total Long-Term Assets	$151.0K	$164.7K	$43.79K
Total Assets	$2.050M	$2.443M	$2.756M
YoY Change	241.55%	424.0%	257.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.941M	$1.894M	$1.598M
YoY Change	54.12%	56.66%	68.93%
Accrued Expenses	$2.615M	$2.457M	$2.250M
YoY Change	39.75%	41.15%	-66.06%
Deferred Revenue
YoY Change
Short-Term Debt	$710.0K	$200.0K	$200.0K
YoY Change	255.0%		-97.03%
Long-Term Debt Due	$1.882M	$1.953M	$1.465M
YoY Change	2652.07%	1432.84%	-91.88%
Total Short-Term Liabilities	$8.824M	$8.494M	$7.825M
YoY Change	148.63%	176.06%	-75.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$85.02K	$96.20K
YoY Change
Total Long-Term Liabilities	$85.02K	$96.20K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.824M	$8.494M	$7.825M
Total Long-Term Liabilities	$85.02K	$96.20K	$0.00
Total Liabilities	$8.909M	$8.590M	$7.825M
YoY Change	151.03%	179.19%	-75.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$248.9M	-$248.1M
YoY Change
Common Stock	$419.5K	$419.4K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.859M	-$6.147M	-$5.069M
YoY Change
Total Liabilities & Shareholders Equity	$2.050M	$2.443M	$2.756M
YoY Change	241.55%	424.0%	257.23%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$713.3K	-$1.078M	-$1.031M
YoY Change	-32.15%	-31.76%	-38.27%
Depreciation, Depletion And Amortization	$2.820K	$2.820K	$3.220K
YoY Change	-12.42%	-12.15%	0.0%
Cash From Operating Activities	-$816.6K	-$877.9K	-$592.2K
YoY Change	11.82%	10.91%	-46.81%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	496.9K	430.4K	-33.53K
YoY Change	-47.03%	-12.12%	-102.46%
NET CHANGE
Cash From Operating Activities	-816.6K	-877.9K	-592.2K
Cash From Investing Activities
Cash From Financing Activities	496.9K	430.4K	-33.53K
Net Change In Cash	-319.7K	-447.5K	-625.8K
YoY Change	-253.96%	48.26%	-348.36%
FREE CASH FLOW
Cash From Operating Activities	-$816.6K	-$877.9K	-$592.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000315545
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	PVCT	Deposit For Purchase Of Preferred Stock DepositForPurchaseOfPreferredStock		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	PVCT	Gain On Forgiveness Of Ppp Loan And Interest GainOnForgivenessOfPPPLoanAndInterest		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021Q2	us-gaap	Restricted Cash RestrictedCash		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	PVCT	Deposit Applied For Purchase Of Series D1 Preferred Stock DepositAppliedForPurchaseOfSeriesD1PreferredStock		usd
	PVCT	Conversion Of Nonamended Notes To Preferred Stock ConversionOfNonamendedNotesToPreferredStock		usd
	PVCT	Conversion Of Amended Notes And Notes To Preferred Stock One ConversionOfAmendedNotesAndNotesToPreferredStockOne		usd
	PVCT	Rightofuse Assets Obtained In Exchange For Operating Lease Liabilities RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36457
	dei	Entity Registrant Name EntityRegistrantName	PROVECTUS BIOPHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0031917
	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 S Gay Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1610
	dei	Entity Address City Or Town EntityAddressCityOrTown	Knoxville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37929
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	594-5999
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	419497119	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84274	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	682984	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1948335	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2423958	usd
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2744	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	5107	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	243394	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	329908	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	2278747	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3441957	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	97215	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	91178	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25799	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31836	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	138863	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39563	usd
CY2022Q2	us-gaap	Assets Assets	2443409	usd
CY2021Q4	us-gaap	Assets Assets	3513356	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1894201	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1287459	usd
CY2021Q4	PVCT	Deposit For Purchase Of Preferred Stock DepositForPurchaseOfPreferredStock	150000	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1990685	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2500000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2331621	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002486	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	68389	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	10578	usd
CY2022Q2	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	14044	usd
CY2021Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	6044	usd
CY2022Q2	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	142693	usd
CY2021Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	238452	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1810000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1260000	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	200000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	200000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42662	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45617	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8494295	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7700636	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	96201	usd
CY2022Q2	us-gaap	Liabilities Liabilities	8590496	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7700636	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419447119	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419447119	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419447119	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419447119	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	419447	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	419447	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241590054	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241440106	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-35511	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34467	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248142721	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246033958	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6147087	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2443409	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3513356	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	321710	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	509315	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	816648	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	602979	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1487764	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1258123	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	583042	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	619038	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1099589	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1144570	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1399690	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1222017	usd
	us-gaap	Operating Expenses OperatingExpenses	2587353	usd
	us-gaap	Operating Expenses OperatingExpenses	2402693	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1077980	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1222017	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2078038	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2402693	usd
CY2022Q2	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	38259	usd
CY2021Q2	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	32144	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	38259	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	32144	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63094	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63094	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-38120	usd
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-452812	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-68984	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-942086	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	139	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-357574	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30725	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-846848	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1579591	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2108763	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3249541	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419447119	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	403628466	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419447119	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	402910628	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1579591	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2108763	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3249541	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-328	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1121	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1044	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-2610682	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2108763	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3249541	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	21913	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	31142	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	40012	usd
	us-gaap	Depreciation Depreciation	6037	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-284	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1078169	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1580712	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2109807	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3249825	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1030922	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-716	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5068918	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-328	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6147087	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-30206357	usd
CY2021Q1	PVCT	Stock Issued During Period Value Issued Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuedUponExerciseOfWarrants	239850	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	19750	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1669950	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	837	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-31615870	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-31615870	usd
CY2021Q2	PVCT	Stock Issued During Period Value Issued Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuedUponExerciseOfWarrants	10660	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1675	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	488	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3541222	usd
CY2021Q2	PVCT	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	27031858	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1579591	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1579591	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1121	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1121	usd
	us-gaap	Depreciation Depreciation	6432	usd
	PVCT	Gain On Forgiveness Of Ppp Loan And Interest GainOnForgivenessOfPPPLoanAndInterest	63094	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2363	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1632	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-143940	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-123230	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	606742	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	252254	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-509315	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	329135	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	152786	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37196	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-42191	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	65811	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	940212	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1470104	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1819619	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	550000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1700000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	153185	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	95387	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-85398	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	250510	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	396815	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1769725	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1044	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	70	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1074333	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49824	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97231	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2032609	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47407	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84274	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47407	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	1948335	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-57426	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-309710	usd
	PVCT	Deposit Applied For Purchase Of Series D1 Preferred Stock DepositAppliedForPurchaseOfSeriesD1PreferredStock	-150000	usd
	PVCT	Conversion Of Nonamended Notes To Preferred Stock ConversionOfNonamendedNotesToPreferredStock	3541222	usd
	PVCT	Conversion Of Amended Notes And Notes To Preferred Stock One ConversionOfAmendedNotesAndNotesToPreferredStockOne	27031858	usd
	PVCT	Rightofuse Assets Obtained In Exchange For Operating Lease Liabilities RightofuseAssetsObtainedInExchangeForOperatingLeaseLiabilities	130422	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zZQCcoOXzMld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_826_zMzcfRYXTTue">Business Organization, Nature of Operations and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of small molecules called halogenated xanthenes (“HXs”), a class entirely owned by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our lead HX molecule is named rose bengal sodium (“RBS”). The Company has established a multi-step approach using quality-by-design principles for synthesizing and manufacturing pharmaceutical-grade RBS by current good manufacturing practice (“cGMP”) and under the guidelines of The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. A second HX molecule has been synthesized, 4,5,6,7-tetrabromo-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenz- ofuran-1,9′-xanthen]-3-one.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Oncology: </i>PV-10<sup>®</sup>, an investigational cancer immunotherapy administered by intralesional (“IL”) injection and an injectable formulation of cGMP RBS, is undergoing clinical study for adult solid tumor cancers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral formulations of cGMP RBS are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pediatric Oncology:</i> IL PV-10 is undergoing preclinical study for pediatric solid tumor cancers.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hematology: </i>Oral formulations of cGMP RBS are undergoing preclinical study for refractory and relapsed pediatric blood cancers (including leukemias).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Virology: </i>Systemic administration of formulations of cGMP RBS are undergoing preclinical study for the novel strain of coronavirus (“CoV”): severe acute respiratory syndrome (“SARS”) CoV 2 (“SARS-CoV-2”).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Microbiology: </i>Different formulations of cGMP RBS are undergoing preclinical study as potential treatments for multi-drug resistant (“MDR”) bacteria.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ophthalmology: </i>Topical formulations of cGMP RBS are undergoing preclinical study as potential treatments for diseases and disorders of the eye.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dermatology: </i>PH-10<sup>®</sup>, an investigational immune-dermatology agent administered as a topical formulation of cGMP RBS, is undergoing monotherapy clinical study as well as preclinical study as a monotherapy and in combination therapy with approved drugs for inflammatory dermatoses.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Animal Health: </i>Different formulations of cGMP RBS are undergoing development as potential treatments for animal cancers and dermatological disorders.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SARS-CoV-2 was first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2032609	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	1948335	usd
CY2022Q2	PVCT	Working Capital Deficiency WorkingCapitalDeficiency	6215548	usd
CY2021Q4	PVCT	Working Capital Deficiency WorkingCapitalDeficiency	4258679	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	42594	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2021Q4	PVCT	Payment To Vendors For Expense And Deposits PaymentToVendorsForExpenseAndDeposits	551665	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z7Guuw0yyXWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zc5W9tqHfq4d">Cash Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20220630_z8ru7P8qPxg4" title="Insured limits">250,000</span>, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of June 30, 2022 and December 31, 2021, the Company had cash, cash equivalents, and restricted cash balances in excess of FDIC insurance limits of $<span id="xdx_90A_eus-gaap--FDICIndemnificationAsset_iI_c20220630_z5MlKaPJZgV5" title="Cash in excess FDIC insured amount">1,782,609</span> and $<span id="xdx_908_eus-gaap--FDICIndemnificationAsset_iI_c20211231_zovSaKKcSPUf" title="Cash in excess FDIC insured amount">2,856,942</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q2	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1782609	usd
CY2021Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	2856942	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zQDj6fSPkeil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zhxtWEe4AzS1">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	116330435	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	194167921	shares
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	259008	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	174533	usd
CY2022Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	56356	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	42871	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1753089	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1560589	usd
CY2022Q2	PVCT	Accrued Other Expenses AccruedOtherExpenses	263168	usd
CY2021Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	224493	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2331621	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002486	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	142693	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	238452	usd
CY2022Q2	us-gaap	Officers Compensation OfficersCompensation	96250	usd
CY2021Q2	us-gaap	Officers Compensation OfficersCompensation	96250	usd
	us-gaap	Officers Compensation OfficersCompensation	192500	usd
	us-gaap	Officers Compensation OfficersCompensation	192500	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1753089	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1560589	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50
	us-gaap	Operating Lease Payments OperatingLeasePayments	38625	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	45784	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	151693	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	24318	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	49311	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50663	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	25669	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	149961	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11098	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	138863	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1990685	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	509315	usd

Files In Submission

Name	View Source	Status
0001493152-22-022049-index-headers.html	Edgar Link	pending
0001493152-22-022049-index.html	Edgar Link	pending
0001493152-22-022049.txt	Edgar Link	pending
0001493152-22-022049-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pvct-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pvct-20220630_lab.xml	Edgar Link	unprocessable
pvct-20220630_cal.xml	Edgar Link	unprocessable
pvct-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pvct-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2022 Q3 Form 10-Q Financial Statement

#000149315222022049 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2022 Q3 Form 10-Q Financial Statement

#000149315222022049 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct